UK markets closed

LENSAR, Inc. (LNSR)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
6.24-0.01 (-0.16%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close6.25
Open6.29
Bid2.50 x 1000
Ask7.05 x 800
Day's range6.18 - 6.51
52-week range5.50 - 8.98
Volume18,752
Avg. volume12,738
Market cap68.881M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-2.20
Earnings date07 Nov 2022 - 11 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est14.00
  • Business Wire

    LENSAR Reports Second Quarter 2022 Financial Results and Provides Business Update

    ORLANDO, Fla., August 08, 2022--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2022 and provided an update on operational initiatives.

  • Business Wire

    LENSAR to Report Second Quarter 2022 Financial Results on Monday, August 8, 2022

    ORLANDO, Fla., August 01, 2022--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s second quarter 2022 financial results will be released before market open on Monday, August 8, 2022. LENSAR’s management will host a conference call and webcast at 8:30 am ET on Monday, August 8, 2022 to discuss the financial results and recent corpor

  • Business Wire

    LENSAR® Receives U.S. FDA Clearance of ALLY™ Adaptive Cataract Treatment System

    ORLANDO, Fla., June 13, 2022--LENSAR, Inc. (NASDAQ: LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced U.S. Food and Drug Administration ("FDA") 510(k) clearance for its next-generation ALLY Adaptive Cataract Treatment System ("ALLY" or "ALLY System"). ALLY is the first FDA-cleared platform to enable cataract surgeons to complete the femtosecond-laser-assisted cataract sur